To review the available literature addressing the role of low-molecular-weight heparin (LMWH) as an alternative to unfractionated heparin (UFH) in percutaneous coronary intervention (PCI) for treatment of non–ST-elevation acute coronary syndromes (NSTEACS).
DATA SOURCES
A MEDLINE search (1966–March 2004) identified pertinent articles using the key words acute coronary syndromes, unstable angina, non–ST-elevation myocardial infarction, low-molecular-weight heparin, enoxaparin, dalteparin, glycoprotein IIb/IIIa receptor antagonists, abciximab, tirofiban, eptifibatide, percutaneous transluminal coronary angioplasty, and percutaneous coronary intervention. The references of these articles were reviewed for additional pertinent references.
STUDY SELECTION AND DATA EXTRACTION
All human trials of LMWH in PCI for treatment of NSTEACS were evaluated. All pertinent studies were included in the review.
DATA SYNTHESIS
Administration of LMWH with or without a glycoprotein IIb/IIIa inhibitor during PCI appears to be similar to UFH in terms of efficacy. LMWH, especially in combination with a glycoprotein IIb/IIIa inhibitor, may increase risk of bleeding compared with UFH.
CONCLUSIONS
Available clinical trials do not provide definitive evidence to suggest superiority of LMWH over UFH when managing NSTEACS during PCI; however, dosing strategies are available if an LMWH is to be used in this setting.
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
. KleinW, BuchwaldA, HillisSE, MonradS, SanzG, TurpieAG, Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation1997; 96: 61–8.
3.
. GurfinkelGP, ManosEJ, MejailRI, CerdaMA, DurontoEA, GarciaCN, Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol1995; 26: 313–8.
4.
. The FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non–Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J1999; 20: 1553–62.
5.
. CohenM, DemersC, GurfinkelEP, TurpieAGG, FromellGJ, GoodmanS, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med1997; 337: 447–52.
6.
. AntmanEM, McCabeCH, GurfinkelEP, TurpieAGG, BerninkPJLM, SaleinD, For the TIMI IIB Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) IIB Trial. Circulation1999; 100: 1593–601.
7.
. MichalisLK, KatsourasCS, PapamichaelN, AdamidesK, NakaKK, GoudevenosJ, Enoxaparin versus tinzaparin in non–ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J2003; 146: 304–10.
8.
. BraunwaldE, AntmanEM, BeasleyJW, CaliffRM, CheitlinMD, HochmanJS, ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. www.acc.org/clinical/guidelines/unstable/unstable.pdf (accessed 2004 May 31).
9.
. BertrandME, SimoonsML, FoxKAA, WallentinLC, HammCW, McFaddenE, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J2002; 23: 1809–40.
. The thrombolysis in myocardial infarction (TIMI) IIA trial investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI IIA. J Am Coll Cardiol1997; 29: 1474–82.
12.
. MartinJL, FryET, SanderinkGJ, AtherleyTH, GuimartCM, GhevalierPJ, Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv2004; 61: 163–70.
13.
. ColletJP, MontalescotG, LisonL, ChoussatR, AnkriA, DrobinskiG, Percutaneous coronary interventions after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation2001; 103: 658–63.
14.
. ChenWH, LauCP, LauYK, NgW, LeePY, YuCM, Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol2002; 14: 439–42.
15.
. LeeDS, BhattDL, MoliternoDJ, PeacockWF, EllisSG, TopolEJ. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol2004; 16: 46–51.
16.
. ChoussatR, MontalescotG, ColletJP, VicautE, AnkriA, GalloisV, A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol2002; 40: 1943–50.
17.
. AslamMS, SundbergS, SabriMN, CookeD, LakierJB. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv2002; 57: 187–90.
. RabahMM, PremmereurJ, GrahamM, FareedJ, HoppensteadtDA, GrinesLL, Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol1999; 84: 1391–5.
22.
. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty–controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb-IIIa blockade. Lancet1998; 352: 87–92.
. SmithSCJr, DoveJT, JacobsAK, KennedyJW, KereiakesD, KernMJ, ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol2001; 37: 2215–38.
25.
. CarnendranL, BorkowskiR, MarkabawiB, WarnerMF. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol2003; 15: 235–8.
26.
. KereiakesDJ, KleimanNS, FryE, MwawasiG, LengerichR, MareshK, Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J2001; 141: 348–52.
27.
. KhoslaS, KunjummenB, GuerreroM, MandaR, RazminiaM, TrivediaA, Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrilin) during nonemergent coronary and peripheral vascular intervention. Am J Ther2002; 9: 488–91.
28.
. FergusonJJ, AntmanEM, BatesER, CohenM, EveryNR, HarringtonRA, Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J2003; 146: 628–34.
29.
. BhattDL, LeeBI, CasterellaPJ, PulsipherM, RogersM, CohenM, Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin study. J Am Coll Cardiol2003; 41: 20–5.
30.
. BlazingMA, de LemosJA, WhiteHD, FoxKAA, VerheugtFWA, ArdissinoD, Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non–ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA2004; 292: 55–64.
31.
. FergusonJJ, CaliffRM, AntmanEM, CohenM, GrinesCL, GoodmanS, Enoxaparin vs. unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA2004; 292: 45–54.
32.
. The TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med1985; 312: 932–6.
33.
. The GUSTO investigators. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med1993; 329: 673–82.
34.
. PetersenJL, MahaffeyKW, HasselbladV, AntmanEM, CohenM, GoodmanSG, Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non–ST-segment elevation acute coronary syndromes: a systematic overview. JAMA2004; 292: 89–96.
35.
. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med1997; 336: 1689–96.
36.
. ColletJP, MontalescotG, GolmardJL, TanguyM, AnkriA, ChoussatR, Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary sydromes. Am Heart J2004; 147: 655–61.
37.
. MarmurJD, AnandSX, BaggaRS, FareedJ, PanCM, SharmaSK, The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol2003; 41: 394–402.
38.
. FoxKAA, AntmanEM, CohenM, BigonziF. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non–ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol2002; 90: 477–82.
39.
. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularization during InStability in Coronary artery disease investigators. Lancet1999; 354: 708–15.
40.
. BriegerD, SolankiV, GaynorM, BoothV, MacDonaldR, FreedmanSB. Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes. Am J Cardiol2002; 89: 1167–70.
41.
. KincaidEH, MonroeML, SalibaDL, KonND, ByerlyWG, ReichertMG. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg2003; 76: 124–8.
42.
. ColletJP, MontalescotG, ChoussatR, LisonL, AnkriA. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol2001; 80: 81–2.
43.
. BrophyDF, WaznyLD, GehrTWB, ComstockTJ, VenitzJ. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy2001; 21: 169–74.
44.
. LawrenceM, MixonTA, CrossD, GanttDS, DehmerGJ. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv2004; 61: 52–5.
45.
. MoliternoDJ, HermillerJB, KereiakesDJ, YowE, ApplegateRJ, BradenGA, A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: results of the Evaluating Enoxaparin Clotting Times (ELECT) study. J Am Coll Cardiol2003; 42: 1132–9.
46.
. CheongB, O'MeallieL, DiezJG. Enoxaparin in percutaneous interventions: when to monitor? A case series. J Invasive Cardiol2003; 15 (suppl): 1–6.
47.
. The Cardiac Catheterization and Antithrombotic Therapy and Tools in the Hospital (CATH) clinical consensus panel. Acute coronary syndromes. Site-, specialty-, and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS and ST-elevation myocardial infarction (STEMI). Interventional Cardiology Consensus Rep 2003: 1–36.
48.
. KalusJS, WhiteCM. Monitoring antifactor Xa activity of the low-molecular-weight heparins in the clinical setting: who, why, how, and when?Conn Med2002; 66: 749–52.
